Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities:
Net income	$ 16,113	$ 47,184	$ 26,545
Adjustments to reconcile to net cash provided by operating activities:
Stock-based compensation expense	10,739	7,063	5,007
Depreciation and amortization	9,355	5,990	4,999
Deferred income taxes	20,188	9,229	5,752
Non-cash development expenses from joint venture	5,290	5,995	7,215
Loss (gain) on disposal of property and equipment	392	(38)	61
Provision for impairment of long-lived assets	976	1,218	7,328
Provision for impairment of accrued interest on note receivable	0	1,032	0
Provision for fair value of contingent value rights	221	0	0
Excess tax benefits from stock-based compensation	(2,200)	(1,700)	(1,852)
Changes in operating assets and liabilities:
Accounts receivable	(34,873)	19,094	(30,017)
Inventories	(1,939)	799	6,207
Income taxes	1,422	(4,454)	(1,673)
Prepaid expenses and other assets	660	(764)	(1,435)
Accounts payable	2,510	3,392	(1,547)
Accrued expenses and other liabilities	(95)	(447)	(109)
Accrued compensation	(3,303)	6,175	3,395
Deferred revenue	(10,863)	(838)	(6)
Net cash provided by operating activities	14,593	98,930	29,870
Cash flows from investing activities:
Purchases of property, plant and equipment	(54,026)	(22,101)	(33,287)
Acquisition of Trubion Pharmaceuticals, Inc., net of cash acquired	0	(17,873)	0
Proceed from maturities of investments	4,250	6,518	0
Purchase of investments	(4,187)	0	0
Repayment/(issuance) of note receivable	0	10,000	0
Net cash used in investing activities	(53,963)	(23,456)	(33,287)
Cash flows from financing activities:
Restricted cash release (deposit)	(3)	(2)	(7)
Proceeds from borrowing on long-term indebtedness and line of credit	27,522	15,000	57,183
Issuance of common stock subject to exercise of stock options	10,026	7,235	4,464
Excess tax benefits from stock-based compensation	2,200	1,700	1,852
Principal payments on long-term indebtedness and line of credit	(15,494)	(33,291)	(48,648)
Payment Attributed to contingent value rights	(10,000)	0	0
Net cash (used in) provided by financing activities	14,251	(9,358)	14,844
Effect of exchange rate changes on cash and cash equivalents	1	(21)	24
Net increase (decrease) in cash and cash equivalents	(25,118)	66,095	11,451
Cash and cash equivalents at beginning of year	169,019	102,924	91,473
Cash and cash equivalents at end of year	143,901	169,019	102,924
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	1,740	2,176	1,627
Cash paid during the year for income taxes	4,280	22,440	15,155
Supplemental information on non-cash investing and financing activities:
Issuance of common stock to acquire Trubion Pharmaceuticals, Inc.	0	61,204	0
Purchases of property, plant and equipment unpaid at year end	$ 15,509	$ 3,519	$ 2,749